Fas-associated phosphatase 1 mediates Fas resistance in myeloid progenitor cells expressing the Bcr-abl oncogene

Leukemia and Lymphoma

Volumn 54, Issue 3, 2013, Pages 619-630

  Huang, Weiqi ^a,b   Bei, Ling ^a   Eklund, Elizabeth A ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Gene regulation; Leukemia

Indexed keywords

BCR ABL PROTEIN; CD38 ANTIGEN; FAS ANTIGEN; FAS ASSOCIATED PHOSPHATASE 1; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; BONE MARROW CELL; CANCER RESISTANCE; CD34 SELECTION; CELL DIFFERENTIATION; CELL POPULATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; EX VIVO STUDY; IN VITRO SELECTION; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION;

ANIMALS; ANTIGENS, CD95; BENZAMIDES; BLOTTING, WESTERN; BONE MARROW CELLS; CELL LINE, TUMOR; CELLS, CULTURED; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION; HUMANS; INTERFERON REGULATORY FACTORS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID PROGENITOR CELLS; PIPERAZINES; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 13; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; U937 CELLS;

EID: 84873356810     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.720979     Document Type: Article

References (34)

1. Driggers PH, Ennist DL, Gleason SL, et al. An interferon gamma-regulated protein that binds the interferon-inducible enhancer element of major histocompatibility complex class I genes. Proc Natl Acad Sci USA 1990;87: 3743-3747.
2. Schmidt M, Nagel S, Proba J, et al. Lack of interferon consensus sequence binding protein transcripts in human myeloid leukemias. Blood 1998;91: 22-29.
3. Holtschke T, Lohler J, Kanno J, et al. Immuno-def ciency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 1996;87: 307-315.
4. Eklund EA, Jalava A, Kakar R. The transcription factors PU. 1, IRF-1 and ICSBP cooperate to increase gp91-phox expression. J Biol Chem 1998;273;13957-13965.
5. Eklund EA, Kakar R. Recruitment of CREB-binding protein by PU. 1, IFN-regulatory factor 1, and the IFN consensus sequence-binding protein is necessary for IFN γinduced p67phox and gp91phox expression. JImmunol 1999;163: 6095-6105.
6. Huang W, Zhu C, Wang H, et al. The interferon consensus sequence binding protein (ICSBP/IRF8) represses PTPN13 gene transcription in Differentiating myeloid cells. J Biol Chem 2008: 283: 7921-7935.
7. Huang W, Zhou W, Saberwal G, et al. Interferon consensus sequence binding protein (ICSBP) decreases beta-catenin activity in myeloid cells by repressing GAS2 transcription. Mol Cell Biol 2010;30: 4575-4594.
8. Schmidt M, Hochhaus A, Nitsche A, et al. Expression of ICSBP in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response. Blood 2001;97: 3648-3650.
9. Oncomine research edition. Ann Arbor, MA: University of Michigan. Available from: www.oncomine.org
10. Konieczna I, Horvath E, Wang H, et al. Constitutive activation of SHP2 cooperates with ICSBP-def ciency to accelerate progression to acute myeloid leukemia. J Clin Invest 2008;118: 853-867.
11. Zhang X, Ren R. Bcr-Abl effciently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood 1998, 92: 3829-3840.
12. Hao SX, Ren R. Expression ofICSBP is down-regulated in bcr-abl-induced murine CML-like disease and forced co-expression of ICSBP inhibits bcr-abl-induced MPD. Mol Cell Biol 2000;20: 1149-1161.
13. Zhu CL, Saberwal G, Lu YF, et al. The interferon consensus sequence binding protein (ICSBP) activates transcription of the gene encoding Neurofbromin 1 (NF1). J Biol Chem 2004;279: 50874-50885.
14. Saras J, Claesson-Welsh L, Heldin CH, et al. Cloning and characterization of PTPL1, a PTP with similarities to cytoskeletal-associated proteins. J Biol Chem 1994;269: 24082-24089.
15. Yanagisawa J, Takahashi M, Kanki H, et al. The molecular interaction of Fas andFap1. JBiol Chem 1997;272: 8539-8545.
16. Roeder I, Horn M, Glauche I, et al. Dynamicmodelingofimatinib-treated CML: functional insights & clinical implications. Nat Med 2006;12: 1181-1184.
17. Michor F, Hughes TP, Iwasa Y, et al. Dynamics of CML. Nature 2005;435: 1267-1270.
18. Larrick JW, Fischer DG, Anderson SJ, et al. Characterization of a human macrophage-like cell line stimulated to Differentiate in vitro: a model ofmacrophage functions. JImmunol 1980;125: 6-12.
19. Wang H, Lindsey S, Konieczna I, et al. Constitutively active SHP2 cooperates with HoxA10-overexpression to induce AML. J Biol Chem 2009;284: 2549-2567.
20. Huang W, Hu L, Bei L, et al. The leukemia-associated fusion protein Tel-platelet-derived growth factor receptor β(Tel-PdgfRβ) inhibits transcriptional repression of PTPN13 gene by interferon consensus sequence binding protein (Icsbp). J Biol Chem 2012: 287: 8110-8125.
21. Eisterer W, Jiang X, Christ O, et al. Different subsets of primary CML stem cells engraft immuno-def cient mice and produce a model of the human disease. Leukemia 2005;19: 435-441.
22. Jamieson CHM, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemia stem cells in blast crisis CML. NEngl JMed 2004;351: 657-667.
23. Minami Y, Stuart SA, Ikawa T, et al. Bcr/abl-transformed GMP as myeloid leukemia stem cells. Proc Natl Acad Sci USA 2008;105: 17967-17972.
24. Drucker BJ, Guilhot F, O'Brien SG, et al. Five-year follow up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355: 2408-2417.
25. Okimoto RA, Van Etten R. Road toward optimal initial therapy for chronic myeloid leukemia. Cur Opin Hematol 2011;18: 89-97.
26. Cortes J, Hochhaus A, Hughes T, et al. Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. J Clin Oncol 2011;29: 524-531.
27. Mitchell B, Deninger M. Risk stratification in newly diagnosed CML. Leuk Lymphoma 2011: 52: 4-11.
28. Miething C, Grundler R, Mugler C, et al. Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment. Proc Natl Acad Sci USA 2007;104: 4594-4599.
29. Turkina AG, Logacheva NP, Stromskaya TP, et al. Studies of some mechanisms of drug resistance in CML. Adv Exp Med Biol 1999;457: 477-488.
30. Kim KM, Lee K, Hong YS, et al. Fas-mediated apoptosis and expression of related genes in human malignant hematopoietic cells. Exp Mol Med 2000;32: 246-254.
31. Lickliter JD, Kratzke RA, Nguyen PL, et al. Fas ligand is highly expressed in acute leukemia and during the transformation of chronic myeloid leukemia to blast crisis. Exp Hematol 1999;27: 1519-1527.
32. Liu WH, Cheng YC, Chang LS. ROS-mediated p38alpha MAPK activation and ERK inactivation responsible for upregulation of Fas and FasL and autocrine Fas-mediated cell death in phospholipase A(2)-treated U937 cells. J Cell Physiol 2009: 219: 642-651.
33. Xiao ZY, Wu W, Eagleton N, et al. Silencing Fas-associated phosphatase 1 expression enhances ef ciency of chemotherapy for colon carcinoma with oxaliplatin. World J Gastroenterol 2010: 16: 112-118.
34. Yao H, Song E, Chen J, et al. Expression of Fap1 by human colon adenocarcinoma: implication for resistance against Fas-mediated apoptosis in cancer. Br J Cancer 2004: 91: 1718-1725.